Polymyxin B, an amphipathic cyclic decapeptide produced by Bacillus polymyxa, is routinely used in the extraction of the components from the periplasmic space of gram-negative bacteria. Vero cytotoxin 1 (VT1) is an Escherichia coli-elaborated subunit toxin which binds to the glycolipid globotriosylceramide (Gal-al-4-Gal 1l-4-Glc-ceramide [Gb3]) and has been strongly implicated in the etiology of the hemolytic uremic syndrome and hemorrhagic colitis. We now show by in vitro glycolipid-binding assays that in the presence of low concentrations of polymyxin B, globotetraosylceramide (GalNAc4l-3Galal-4Gal,l-4Glc-ceramide [Gb4]) is also recognized by both the VT1 B (binding) subunit and holotoxin. Melittin, a 26-amino-acid cyclic peptide of similar amphipathic nature, produced the same effect, whereas a hydrophobic blocking agent did not. Triton X-100 did not increase binding of VT1 to Gb4 but prevented glycolipid binding in toto at concentrations above 0.5%. Caution is therefore advised in the analysis of VT1 glycolipid binding in the presence of amphipathic peptides.
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Vero cytotoxin (VT) (or Shiga-like toxin)-producing Escherichia coli have been strongly implicated in the etiology of hemorrhagic colitis (25) and the hemolytic uremic syndrome (16) . These toxins are subunit proteins comprising an A subunit which inactivates the 28S rRNA of susceptible cells and a pentamer of smaller B subunits which bind to a cell surface receptor to facilitate entry of the cytotoxic subunit into cells. The B subunit recognizes the glycolipid globotriosylceramide (Gb3), and binding is specific for glycosphingolipids containing a terminal Galal-4Gal residue (20) . Several variants of these toxins have been described, most notably VT1 (18) , VT2 (17, 26) , and Shiga-like toxin II (27) (VT2 and Shiga-like toxin II are not equivalent [10] ). All these toxins, including Shiga toxin itself (12) , share the same glycolipid-binding specificity (7) . Recently a further variant, isolated from pigs with edema disease (edema disease toxin VTE or Shiga-like toxin IIv), was described which although highly homologous with other members of the VT family, particularly VT2, bound to an additional glycolipid, globotetraosylceramide (Gb4), the next homolog in the globo series of neutral glycosphingolipids, containing a terminal P1-3-linked N-acetylgalactosamine residue (7). These toxins have been cloned (11, 23, 28) and sequenced (6, 13) , and studies are currently in progress to determine the amino acids involved in the glycolipid-binding site.
Polymyxin B is an antibiotic routinely used in extraction of these toxins from the intact bacterium. The peptide (Mr, 1,202.5) selectively permeabilizes the outer membrane of E. coli, releasing the contents of the periplasmic space (4), thereby increasing the specific activity of toxin extracts (15) . Caution is now advised in the analysis of glycolipid binding in the presence of this peptide, since we present data to show that the glycolipid-binding specificity of VT1 is VT1 B subunit (K. Ramotar et al., Biochem. J., in press). The expression product was extracted from the bacteria by three techniques.
(i) Polymyxin B. The standard polymyxin procedure of Karmali et al. (15) was used. Overnight 2-ml broth cultures were harvested, the pellets were suspended in polymyxin B (2 ml of 1.7 mM polymyxin B or 0.3 ml of 0.12 mM polymyxin B), incubated at 37°C for 1 h, and pelleted, and the supernatants were diluted to 10 ml to yield final polymyxin B concentrations of 0.33 mM (high) or 3.7 ,uM (low) (assuming 100% recovery in the supernatant).
(ii) Osmotic shock. Overnight 2-ml broth cultures were harvested, pellets were suspended in 2 ml of 30 mM Tris-20% sucrose-i mM EDTA (pH 8.0) (TSE buffer), incubated at 30°C for 10 min, and reharvested. The pellets were resuspended in 1 ml of TSE, centrifuged, vigorously suspended in 1 ml of ice-cold water, stirred for 10 min, and pelleted, and the supernatants were collected (22) .
(iii) Spheroplast preparation. Overnight 2-ml broth cultures were harvested, the pellets were suspended in 2 ml of TSE buffer, stirred for 10 min at 4°C, incubated with 5mg of lysozyme per ml for 30 min at 37°C, and pelleted, and the supernatants were collected (1).
Glycolipid binding. The binding of VT1 holotoxin and the VT1 B subunit was assayed by a TLC overlay procedure previously described (20) . Purified glycolipids (2 , specific rabbit anti-VT1 polyclonal serum (neutralization titer, 1,024; diluted 1:100) followed by goat anti-rabbit immunoperoxidase conjugate (diluted 1:2,000), with 4-chloro-1-naphthol as the substrate (20 by comparison with a similar plate visualized for carbohydrate with orcinol spray. Control TLC plates without toxin were also sprayed with orcinol after the procedure to monitor any possible glycolipid loss during washing.
The effect of polymyxin B on binding of [1251] VT1 to Gb4 in a lipid mixture was quantitated in microtiter wells. Gb4 (or DGDG as a control) was mixed with phosphatidylcholine and cholesterol (to facilitate immobilization) at a ratio of 1:5:2.5 in methanol; 100 RI (100 ng of glycolipid) was added to the wells, allowed to dry overnight, and blocked with 3% bovine serum albumin in TBS for 2 h. The wells were then washed three times with 50 mM TBS (pH 7.4). Dilutions of
[125I]VTI (specific activity, 3.96 x 104 cpm/,ug of protein)
were made with and without polymyxin B (0.25 mM), added to the wells, and incubated for 2 h. The wells were thoroughly washed with 50 mM TBS (pH 7.4) and excised, and the radioactivity counted in a Beckman 5500 Gamma Counter. The entire procedure was performed at room temperature. Figure 1 shows the analysis of glycolipid-binding specificity by TLC overlay of the expression products of the recombinant B-subunit gene. E. coli(pJLB120) was extracted with low or high polymyxin B concentrations, by osmotic shock, or with lysozyme. Binding of the B subunit to CDH, Gb3, and Gb4 was compared. In the absence of polymyxin B, binding was restricted to Gb3 (Fig. lc to e) . However, the presence of polymyxin B at a concentration as low as 3.7 ,uM resulted in significant additional binding to Gb4 and CDH ( Fig. la and b) .
RESULTS
Glycolipid-binding specificity determined by TLC overlay of purified recombinant VT1 holotoxin is shown in Fig. 2 . Increasing concentrations of polymyxin B were added to the overlays during the VT incubation. As indicated above, binding to CDH and Gb4 increased in the presence of polymyxin B. However, no binding to DGDG was observed at any polymyxin B concentration. VT1 binding in the presence of polymyxin B was eliminated for CDH samples treated with a-galactosidase (Fig. 2f) . A linear increase in the binding of VT1 to Gb4 in microtiter plates was observed in the presence of polymyxin B. Binding of VT1 to DGDG was unaffected (Fig. 3 ). An approximate fourfold increase in binding was observed over a VT concentration of 1 to 10 jig per well. (4). We therefore investigated the effect of a known hydrophobic blocking agent, as well as another amphipathic cyclic peptide, melittin, known to interact with glycolipids (8), on the glycolipid-binding specificity of VT1. Melittin caused the same change in binding specificity of VT1 such that Gb4 was also recognized (Fig. 4, row b) . The hydrophobic blocking agent TNS (soluble only up to a concentration of 0.12 mM) did not alter binding specificity (Fig. 4, row c) . Triton X-100 also did not alter binding specificity but inhibited all binding at a concentration of 0.5% (Fig. 4, row d) .
In order to determine the specificity of polymyxin-mediated VT1 binding, we examined VT1 binding to other glycosphingolipids in the presence of polymyxin B (Fig. 5) . The increased binding was found to be specific for Gb4. Gangliosides, and more notably asialo GM1, another ceramide tetrahexoside, were not bound.
DISCUSSION
Carbohydrate recognition is a common motif for microorganisms and their toxic products, and many of the receptors are glycolipids (14) . VT1 holotoxin (20) and, we now show, the VT1 B subunit specifically recognize the glycolipid Gb3, and there is substantial evidence that this glycolipid acts as the functional receptor for VT1 (5, 21) . Galabiosylceramide (5) and P1 glycolipid (19) (both containing terminal Galal4Gal) have also been shown to bind VT. Our study clearly shows that in the presence of polymyxin B or melittin (small amphipathic peptides), the toxin and the B subunit are also capable of recognizing Gb4. The observed increase in binding to CDH in the presence of polymyxin B was due to galabiosylceramide in this preparation, since VT binding could be abolished by pretreatment with a-galactosidase (the gross glycolipid content, as detected by orcinol spray, was unaffected by treatment with this enzyme [results not shown]).
Although melittin has been reported to interact with glycosphingolipids as a function of carbohydrate chain length (8), the change in VT1 binding specificity was not directly related to carbohydrate chain length, since asialo GM1, a similar ceramide tetrahexoside in which the terminal sugars are essentially reversed, was not recognized (Fig. 5) . Moreover, the change in binding was not a result of nonspecific toxin-peptide-glycolipid interaction since (i) the binding specificity did not change to include unrelated glycolipids such as DGDG, GM1, asialo GM1, or GM2; and (ii) the toxin did not bind directly to melittin or polymyxin B spotted on nitrocellulose paper (results not shown). Our finding that the effect of polymyxin B on VT binding was restricted to glycosphingolipids containing the Gal al4Gal structure may suggest a mechanism of action. Gb4 differs from Gb3 by an additional terminal p1-3-linked Nacetylgalactosamine residue but is not recognized by VT1 (20) . This has been interpreted to suggest that the 3' position of the terminal a-Gal of Gb3 must be free for VT binding. Alternatively, the terminal GalNAc residue of Gb4 may contain a structural feature which prevents binding, which, when masked by polymyxin B or melittin, is no longer inhibitory. Such masking might result from a change in the glycolipid conformation in the presence of polymyxin B, allowing VT1 to bind to an internal a-Gal residue. However, the glycolipid-binding site nevertheless has limited tolerance since no binding to Forssman glycolipid (GalNAcal3GaINAcI31-3Galal-4GalPl-4GlcpI1-ceramide) was observed in the presence of polymyxin B (data not shown), despite the presence of an internal Galal-4Gal. Binding of VT to galabiosylceramide might be limited by the close apposition of the ceramide moiety. Such VTE (pig edema toxin) has been shown to bind primarily to Gb4 (7) . Studies are currently under way to determine which residues are responsible for this specificity. It is interesting that the addition of polymyxin B can change the binding specificity of VT1 to a specificity similar to that seen for VTE. The VT family thus provides a unique opportunity to study the molecular basis of such specific glycolipid recognition.
The data presented here demonstrate that low concentrations of certain amphipathic agents significantly alter the glycolipid-binding specificity of the bacterial toxin VT1. Thus, caution is advised when preparing toxin extracts for use in binding studies. The use of purified toxin or an alternate extraction procedure (lysozyme or osmotic shock) would eliminate spurious results.
